Your session is about to expire
← Back to Search
LY3556050 + Metformin + Iohexol for Healthy Subjects
Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 through 13 days postdose
Awards & highlights
Study Summary
The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose on day 1 through 13 days postdose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 through 13 days postdose
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Metformin
Metformin
Trial Design
1Treatment groups
Experimental Treatment
Group I: LY3556050 + Metformin + IohexolExperimental Treatment3 Interventions
LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3556050
2021
Completed Phase 2
~520
Iohexol
2016
Completed Phase 4
~1920
Metformin
2006
Completed Phase 4
~2430
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,906 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,662 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger